Microbot Medical Inc   (MBOT)
Other Ticker:  
Price: $1.2596 $-0.01 -0.694%
Day's High: $1.28 Week Perf: -2.36 %
Day's Low: $ 1.25 30 Day Perf: -1.59 %
Volume (M): 26 52 Wk High: $ 4.37
Volume (M$): $ 33 52 Wk Avg: $1.82
Open: $1.28 52 Wk Low: $1.00

 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 9
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Microbot Medical Inc
Microbot Medical Inc is a medical device company that specializes in the development and commercialization of innovative robotic technologies designed to improve the minimally invasive surgery experience. The company focuses on the development of robotic systems for various applications, including urology, gynecology, and gastrointestinal procedures. Their devices aim to assist surgeons with precise and controlled movements, ultimately enhancing the effectiveness of surgical procedures while reducing invasiveness and improving patient outcomes.

   Company Address: 288 Grove Street Braintree 2184 MA
   Company Phone Number: 875-3605   Stock Exchange / Ticker: NASDAQ MBOT
   MBOT is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Microbot Medical's Expansion of US Clinical Infrastructure Sets Stage for its First in Human Clinical Study after Successful Pre-Clinical Milestone Achievement

Published Thu, Jan 18 2024 12:20 PM UTC

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical StudyMicrobot Medical, a leading medical robotics company, continues to make significant strides in the development of its groundbreaking technology. Following the recent positive results of its pivotal Good Laboratory Practice (GLP) pre-clini...

Clinical Study

Propelling Medicine into the Future: Evidence of Success for Microbot Medical?s Innovative Pre-Clinical GLP Study

Published Thu, Dec 28 2023 12:30 PM UTC

Microbot Medical, a trailblazer in the field of nano-robotic medical devices, has achieved landmark success with the completion of its latest good laboratory practice (GLP) pivotal pre-clinical study. This groundbreaking study achieved all predefined objectives, outcomes that will, in no uncertain terms, be supporting the company?s Investigational Device Exemption (IDE) subm...


Microbot Medical and Corewell Health Enter Future of Medicine with Telerobotic Endovascular Surgery

Published Thu, Dec 14 2023 1:15 PM UTC

Microbot Medical and Corewell Health have initiated a partnership that is set to redefine the landscape of surgical medicine. They have embarked on a journey to establish the use of LIBERTY Endovascular Robotic Surgical System for remote tele-robotic and endovascular surgeries.
Endovascular surgery has revolutionized modern medicine. This minimally invasive procedur...

Clinical Study

Microbot Medical Successfully Completes GLP Pivotal Pre-Clinical Study, Clears Path for IDE Submission and Human Clinical Trials

Published Thu, Dec 7 2023 1:00 PM UTC

In a recent press release, Microbot Medical announced the successful completion of its Good Laboratory Practice (GLP) pivotal pre-clinical study. This accomplishment represents a critical milestone for the company as it prepares to submit an Investigational Device Exemption (IDE) to commence human clinical studies. The final histopathology and lab report further supplem...

Microbot Medical Inc

Microbot Medical Inc Reports Stable Revenue Performance in Q2 2023 with Potential Implications for the Company's Future

Microbot Medical Inc recently released their financial results for the earnings cycle of fiscal April to June 2023. While the stockholders did not anticipate any changes in revenue, attention was drawn to the company's operating loss, which stood at $-2.324 million during the same period. This article aims to interpret these financial results and discuss the potential implications for the company going forward.
1. Stable Revenue Performance:
Despite the lack of anticipated changes, it is crucial to assess the stability of Microbot Medical Inc's revenue. Although not explicitly mentioned, the consistent revenue stream is a positive sign for the company, suggesting a reliable and predictable customer base.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com